REMARKS

Claims 1 and 9 are currently pending in this application. The Action indicated that claim 1 is no longer rejected and is in condition for allowance. Claim 9 stands rejected under 35 U.S.C. §112, first paragraph because the specification is allegedly not enabled for a method of treating cystic fibrosis wherein an amount of ethyl nitrite is administered to *prevent* accumulation of mucus, bronchoconstriction and bacterial growth. However, the Action indicated that the specification is enabled for a method of treating cystic fibrosis wherein an amount of ethyl nitrite is administered to *lessen* accumulation of mucus, bronchoconstriction and bacterial growth. The Action further pointed out that Applicants could overcome this rejection if claim 9 were amended to recite "lessen" instead of "prevent." Applicants wish to thank the Examiner for this helpful suggestion, and have amended claim 9 accordingly, noting that (as highlighted by the Action on page 5) support for the term "lessen" is found in the term "ameliorate" as found in claim 9.

Consequently, the rejections set forth in the Office Action mailed April 12, 2005 are overcome by amendment, and Applicants respectfully request that this ground of rejection be withdrawn

CONCLUSION

Applicants respectfully contend that all conditions of patentability are met in the pending claims as amended or as originally presented. Allowance of the claims is thereby respectfully solicited.

The Examiner in charge of this application is invited to contact the undersigned representative as indicated below if it is believed to be helpful.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Telephone:

312-913-0001

Facsimile: 312-

Date: July 12,2005

312-913-0002